Voyager Therapeutics stock gets Wells Fargo Buy rating and USD 10 target

Published on 10/06/2026 at 13:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A Wells Fargo Buy rating dated October 2, 2026, sets a USD 10.00 target for Voyager Therapeutics stock. Q2 revenue was USD 3.17 million.

VYGR, US92915B1061, Illustration mit AI erstellt.

Voyager Therapeutics (ISIN US92915B1061) stock was last at USD 2.46 on Nasdaq on October 5, 2026, up 0.41 percent from the prior close and valued at USD 148.6 million. The immediate catalyst is Wells Fargo's maintained Buy rating and USD 10.00 price target, reported on October 2, 2026.

Wells Fargo keeps its Buy rating

According to Markets Insider on October 5, 2026, Wells Fargo maintained its Buy rating on Voyager Therapeutics in a report released October 2 and kept the price target at USD 10.00. The target lies 306.5 percent above the October 5 Nasdaq price of USD 2.46.

The analyst view arrives against a weak share-price backdrop. Voyager Therapeutics stock traded between USD 2.39 and USD 5.55 over the 52-week period ending October 5, leaving the latest price USD 3.09 below the yearly high.

Q2 revenue fell to USD 3.17 million

Voyager Therapeutics lists its second-quarter 2026 financial and operating results release on August 6, 2026. The quarter ended June 30, 2026, and the company reported revenue of USD 3.17 million and a GAAP net loss of USD 24.47 million.

As Markets Insider reported, revenue compared with USD 5.20 million in the year-earlier quarter, while the GAAP net loss narrowed from USD 33.38 million. The figures show a smaller quarterly loss alongside lower revenue, making pipeline progress and cash management central to the valuation case.

Consensus target stays above USD 14

Investing.com lists 11 analysts with Buy ratings, zero Hold ratings and zero Sell ratings for Voyager Therapeutics. Its average 12-month price target is USD 14.889, with a low target of USD 8.00 and a high target of USD 25.00.

At USD 2.46, the consensus target lies 505.2 percent above the Nasdaq price. That spread reflects the high-risk profile of a clinical-stage biotechnology company, where future value depends on clinical progress rather than current earnings.

VYGR stock remains near its yearly low

Voyager Therapeutics stock was last at USD 2.46 on Nasdaq on October 5, 2026, at 4:00 p.m. ET, with volume of 1,391,859 shares. The next scheduled earnings date listed by Investing.com is November 10, 2026.